创胜集团
TRANSCENTA

COMPANY PRESENTATION

March 2023

Disclaimer

- The information and opinions contained in this presentation are provided as of the date of this presentation, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation.
- This presentation contains statements that constitute forward-looking statements. These statements can be recognized by the use of words such as “expects”, “plan”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning or intent. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company has no obligation and does not undertake to revise forward-looking statements contained in this presentation to reflect future events or circumstances.
- This presentation is being presented solely for your information and for your use and may not be copied, reproduced or redistributed to any other person in any manner without the Company’s prior written consent. Unauthorized copying, reproduction or redistribution of this presentation could be limited or prohibited by the securities laws of various jurisdictions. By attending this presentation, participants agree not to photograph, copy or otherwise reproduce these materials during the presentation or while in the conference room.
- The company cannot guarantee that it will be able to develop, or ultimately market, any of its drug candidates successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

Today's Agenda

Overview	01
Business	02
Financial & Outlook	03
Q&A	04

01

PART 01

Company Overview

创胜集团
TRANSCENTA

Company Overview

An Integrated Organization with Global Footprint

Lead
Discovery Translational Research

Industry Leading
Technology Platforms

Global
Clinical Strategy & Execution

World-Class
CMC & CDMO Capability



Company Overview

Achievements in 2022

5

Ongoing Clinical Programs

8

New Patent Granted

~100%

YoY

Total Revenue Growth

Clinical Development

- **1** — TST001 to start Ph3 in 2023
- **2** — New IND clearances
- **11** — Data read-outs and scientific presentations

Patents and Research

- **51** — New Patent Application Filings
- **3** — New Pipeline Candidates

CDMO Business

- **101.9m** RMB — Total Revenue
- **+80%** — External Contract Value Growth
- **30+** — New Clients for CDMO

02

PART 02

Business

创胜集团
TRANSCENTA

Business

Pipeline Highlights

Oncology

Antibody-Based Approach Targeting
Cancer Cells, Tumor Stromal Cells, Angiogenesis and Immune Cells

TST013
ADC

TST012
mAb

TST010
T regulatory cell depleting mAb

TST003
(First-In-Class) Novel Target

TST005
(Best-In-Class) PDL1-TGF-β



MSB0254
(Differentiated) VEGFR2

Osemitamab (TST001)
Best-In-Class anti-CLDN18.2

Gastric Cancer

Pancreatic Cancer

Peri-operative Gastric Cancer

Non-small Cell Lung Cancer

Non-Oncology

Expand Clinically Validated Targets
in Bone and Kidney Diseases

TST002
(Differentiated) Sclerostin

TST004
(Best-In-Class) MASP2

TST008
(First-In-Class) Bispecific

TST801
(First-In-Class) Bispecific

Business

Osemitamab (TST001)

CLDN18.2 is a Clinically Validated Target
– TST001 as a Next Generation Agent Targeting Broader Population in Combination with Checkpoint Inhibitors

SPOTLIGHT and GLOW results:

- Significant improvements PFS and OS
- In combination with chemotherapy
- 38% of patients are eligible (CLDN18.2+ defined as ≥ 75% of cells 2+ or 3+)

SPOTLIGHT
mFOLFOX6+/-Zolbetuximab



GLOW
CAPOX+/-Zolbetuximab



GLOW discussion by Pr Janjigian (MSKCC)







Business

Osemitamab (TST001)

The 2nd Leading Anti-CLDN18.2 mAb with a Differentiated Profile vs. Zolbetuximab

BIC / FIC Potentials

Humanized antibody

Higher binding affinity

Enhanced ADCC

Reduced fucose in Fc and enhanced FcR binding with NK cell and ADCC activity (30-100 fold)

Enhanced ADCC activity for CLDN18.2 low expressing gastric cancer cells



Significantly better than Zolbetuximab

MKN45-CLDN18.2 (40%) Gastric Tumor Model



7/10 in Osemitamab Group vs. 0/10 in IMAB362 Group Achieved Tumor Clearance

BxPC3-CLDN18.2 (90%) PDAC Tumor Model



H146 (CLDN18.2 90%) SCLC Tumor Model



DV90 (CLDN18.2 90%) NSCLC Tumor Model



**: $p<0.01$

Business

Osemitamab (TST001)

Robust Anti-tumor Activities Seen in the First Line G/GEJC Patients Regardless of the Claudin18.2 Expression Levels

(≥10%, ≥1+ by LDT assay)

TranStar102

Encouraging Safety and Efficacy in Dose Expansion

In combination with CAPOX

73.3%

11 out of 15 Patients achieved **PR(c+uc)**

26.7%

4 out of 15 patients achieved **SD**

Mostly grade **1-2**

TRAEs

Treatment Duration and Tumor Assessment



Best Percent Tumor Reduction from Baseline in Tumor Assessment



Business

Osemitamab (TST001)

CDx Ready for Phase 3 in 1L G/GEJC. Better Specificity for Enabling Patient Selection in Tumors beyond GI Cancers



GC182: Transcenta produced based on publicly available information. 40x

Negative nonspecific staining - (≤1) at A – 10x, B – 20x, C – 40x Tumor-membrane staining of GC at Left– 10x, Mid– 20x, Right– 40x

Status

- Developed a mouse mAb (clone 14G11) **binds to CLDN18.2 specifically**
- Collaborated with **a global CDx development partner**
- Demonstrated its **specificity, robustness, and commercial viability**
- Initiated **GMP CDx kit manufacturing** to support the pivotal trial

Synergy Demonstrated between Targeted Therapy TST001 and Checkpoint Inhibitor Nivolumab

Potential MOA for Synergy with PD1/Chemo



Adapted from: Cancer May 2021 • VOL 127; p1553-1567;

CLDN18.2 (100%)/PDL1+ Syngeneic Model



CLDN18.2 (>95%)/PDL1-Negative PDX Model



Leapfrog Competition by Accelerating PD1 Combination in the 1L G/GEJC

TranStar102 NCT04495296

Cohort G: TST001 + Nivolumab + CAPOX – 1L G/GEJ cancer

Safety run-in:
- TST001 6mg/kg + Nivolumab + CAPOX Q3W N=3-6
- TST001 3mg/kg + Nivolumab + CAPOX Q3W N=3-6

Expansion (CLDN18.2 expression):
- TST001 6mg/kg + Nivolumab + CAPOX Q3W N= ~20
- TST001 3mg/kg + Nivolumab + CAPOX Q3W N= ~20

Cohort H: TST001 + Nivolumab – 2 or 3L G/GEJ cancer

Safety run-in:
- TST001 6mg/kg + Nivolumab Q3W N=3-6
- TST001 3mg/kg + Nivolumab Q3W N=3-6

Expansion (CLDN18.2 selected):
- TST001 6mg/kg + Nivolumab Q3W N= ~20

ASCO Gastrointestinal Cancers Symposium

TranStar101 NCT04396821

Cohort A: TST001 + Nivolumab + FOLFOX6 – 1L G/GEJ cancer

1:1
- Cohort A1: TST001 2mg/kg Q2W + Nivolumab + mFOLFOX6
- Cohort A2: TST001 4mg/kg Q2W + Nivolumab + mFOLFOX6

Lead-in | Expansion (CLDN18.2 selected)

Totally 15 subjects with CLDN18.2 expressing cancer for each dose

Cohort B: TST001 + Nivolumab – 2 or 3L G/GEJ cancer

Safety run-in:
- TST001 3mg/kg Q3W + Nivolumab N=3-6
- TST001 6mg/kg Q3W + Nivolumab N=3-6

Expansion (CLDN18.2 selected):
- TST001 RD Q3W + Nivolumab

30 subjects in total in Cohort B

TranStar301 Global Phase III in Q3 2023

Business

Osemitamab (TST001)

2022

01

- CMC readiness obtained
- CDx assay developed and optimized

02

- Reported exciting Ph1b data for osemitamab (TST001) + chemo combo at ESMO 2022

03

- Initiated Ph1b trials for osemitamab (TST001) + Nivo/chemo combo in both US/CN

2023

Phase 3 ready – Q3 2023

TranStar301

Osemitamab (TST001) + Nivolumab + Chemo

1L G/GEJ adenocarcinoma

Additional plans for:

- Peri-operative G/GEJ cancer
- PDAC
- NSCLC

Business

Osemitamab (TST001)

Global Program to Develop Osemitamab as the Cornerstone Treatment in CLDN18.2 Expressing Tumors



Business

Osemitamab (TST001)

The Promise of Osemitamab (TST001)

Well validated target
&
differentiated profile

- ADCC enhanced
- CLDN18.2 specific
- Activity in CLDN18.2 low expressors

2nd most advanced program globally
with phase 3 ready for 1L mGC

- Accelerating the development in a broader CLDN18.2+ population
- Supported by clinical and translational data package

CDx
and
CMC ready

- CDx more specific, supporting global trials & multiple indications
- CMC materials approved by FDA & NMPA
- Low cost of goods

Global Development Plan with Potential for Multiple Indications

- Multi-billion dollar market potential
- Immediate/short term priorities:
  - Phase III in 1L G/GEJ cancer,
  - On track to be initiated Q3 2023
- Mid/Longer term:
  - Peri-operative G/GEJ, PDAC, NSCLC and other indications

Milestones in 2022

Jan
- ✓ 1st patient enrolled and dosed in BTC
- ✓ 2022 ASCO GI

Feb
- ✓ 1st patient dosed in chemo combo for 1L BTC

Mar
- ✓ IGCC 2022
- ✓ Collaboration with BMS

Apr
- ✓ Passed audit of European Union QP

Jun
- ✓ ASCO 2022

Sep
- ✓ ESMO 2022
- ✓ **1st G/GEJ patient dosed** combination with nivolumab +/- chemotherapy

Nov
- ✓ **SITC 2022**
- ✓ **Phase III preparation**

Business
TST003

First-In-Class mAb with Potential Anti-tumor Activities in Multiple Tumor Types

MoA





Green: Stromal fibroblast

Dongre, A., et al Cancer Discovery 2020 DOI: 10.1158/2159-8290.CD-20-0603

Gremlin1

- Target highly expressed in stromal cells in tumor microenvironment
- Targeting CPI resistant/ineligible solid tumors (including Prostate cancer, NSCLC, CRC, ESCC, GC, PADC, Breast Cancer etc)

Efficacy

- Single agent activity in PDL1 negative/ refractory PDX model
- Potent anti-tumor activity in castration resistant prostate cancer (CRPC)
- Additional efficacy studies are ongoing in multiple tumor types

Publication


nature cancer

nature cancer ARTICLES

https://doi.org/10.1038/s43018-022-00380-3

Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer

Chaping Cheng[1,7], Jinming Wang[1,7], Penghui Xu[1], Kai Zhang[1], Zhixiang Xin[1], Huifang Zhao[1], Zhongzhong Ji[1], Man Zhang[2], Deng Wang[1,2], Yuman He[1], Na Jing[1,2], Liancheng Fan[1], Kaiyuan Liu[1], Fei Li[3], Chengcheng Liu[1], Yiming Gong[1], Suli Cui[4], Zhe Sun[4], Di Sun[4], Xinlai Yao[4], Hongjun Li[4], Jian Zhang[5], Pengcheng Zhang[6], Baijun Dong[1], Wei Xue[1], Xueming Qian[4], Wei-Qiang Gao[1,2] and Helen He Zhu[1]

Status

- US & China IND Cleared by FDA and CDE
- An IHC assay has been developed for Grem1 expression detection
- **First patient dosed in March 2023**

A Well Differentiated Monoclonal Antibody for Bone Diseases, Licensed from Eli Lilly with Phase II Data in US and Japan

Dual Mechanisms

Dual effect target



Favorable Characteristics

Efficacy	17% BMD increase in Spine and 6.2% in total hip at week 52 in Phase II study
Safety	Well tolerated and No cardiovascular risk observed
Frequency	2-3 monthly IV infusion with improved compliance
Benefit	Local production with competitive COGs
Status	**Completed enrollments of all dose cohorts with encouraging BMD increasing activity observed**

Status

- **Filed a supplementary application to current China IND for Phase IIa study in March 2023**
- **To initiate dose-confirmation Phase II study in 2023 to enable registrational study in 2025**

BMD: bone mineral density (BMD)

An Anti-MASP2 Antibody with Differentiated Properties

Multiple Potential Indications

C3G/ **IgA nephropathy (IgAN)**
Lupus nephritis/MN/aHUS

AMD/STGD1/Uveitis



PNH/AIHA/TMA



Virus infection trigged complements over-action in multi organ injury

Superior Product Profile

Dosing

- Subcutaneous formulation
- Potentially less frequent dosing

Binding affinity

- High binding affinity
- Specific to MASP-2 in the Lectin pathway

PK/PD

- Long lasting target inhibition in cynomolgus monkey

Status

- Presented preclinical data at 2022 ISN Frontiers Meetings
- Received **IND clearance from FDA** in 2022
- **China IND** is ongoing

Business

TST012 & TST013

Emerging Pipeline of Oncology Drug Candidates



TST012

- ADCC enhanced mAb candidate for gastric cancer, lung cancer etc.
- Lead antibody selected
- TST012 showed potent anti-tumor activities in preclinical tumor model
- IND enabling study to start
- Benchmark program in Ph3

TST013

- ADC product candidate for breast cancer and other solid tumors
- Lead antibody selected
- TST013 showed high affinity binding and potent cytotoxicity in preclinical target positive tumor cells
- IND enabling study to initiate
- Benchmark program in Ph2b

Business

TST008 & TST801

Emerging Pipeline of Auto-Immune Drug Candidates



TST008

- FIC bispecific antibody targeting MASP2 and receptors involved in regulating B cell activation and differentiation
- Target indications: SLE, LN & IgAN
- Lead molecule selected showed a potent inhibition on MASP2 dependent complement activation and sustainable reduction of B cells in vivo
- Benchmark program at Ph3
- IND enabling study to initiate



TST801

- FIC bifunctional antibody targeting receptors involved in regulating B cell activation and differentiation
- Target indications include SLE, LN and IgAN
- Lead molecule selected and showed a potent and sustainable reduction of B cells in both in vitro and in vivo preclinical models
- Benchmark mAb approved
- IND enabling study to initiate

Business

Diversified and Differentiated Pipeline

	Drug candidate	Target		Indications	Clinical trial region	Preclinical	IND	Phase 1a	Phase 1b/ Phase 2a	Pivotal Phase 2b / Phase3	Rights	Partner
Oncology	Osemitamab (TST001)	Claudin 18.2	GC	1L	China	Combo with Chemo					Global	In-house
				1L	Global	Combo with Nivolumab/Chemo						
				2/3L	Global	Combo with Nivolumab						
				2L	Global	Combo with Chemo						
				Late-line	Global	Mono						
			PDAC	Late-line	Global	Mono						
				1L	Global	Combo with Chemo						
			BTC	1L	Global	Combo with Chemo						
			Other solid tumors	Late-line	Global	Mono						
	MSB0254	VEGFR2		Solid tumors	China	Mono					Global	In-house
	TST005	PD-L1/TGF-β Bi-functional		Solid tumors (HPV+ and NSCLC, etc)	Global	Mono					Global	In-house
	TST003	Gremlin1 (FIC)		Solid tumors	Global	Mono					Global	In-house
	TST006	Bi-specific		Solid tumors	Global	Mono					Global	In-house
	TST010	Undisclosed ADCC enhanced mAb		Solid tumors	Global	Mono					Global	In-house
	TST012	Undisclosed		Solid tumors	Global	Mono					Global	In-house
	TST013	Undisclosed ADC		Solid tumors	Global	Mono					Global	In-house
	MSB2311	PD-L1		TMB-H solid tumors	China	Mono					Global	In-house
				Solid tumors	China	Combo with VEGFRi						
Non-oncology	TST002	Sclerostin		Osteoporosis	China	Mono			US Ph II Completed		Greater China	Lilly
	TST004	MASP2		IgA nephropathy, TMA	Global	Mono					Global	ALEBUND
	TST008	MSAP2 Bi-Specific (FIC)		SLE	Global	Mono					Global	In-house
	TST801	Bi-specific		SLE/LN/IgAN	Global	Mono					Global	In-house

Business

CMC & CDMO

Flawless Execution with Increased Efficiency, Global Quality Standard and Commercial Manufacturing Readiness



Faster

Industry Leading perfusion productivity **of > 7g/L-day, > 15-fold** increase in output

Quality

- **>30 new clients**
- Expanded DP fill & finish capability

Significant Cost saving

Proprietary CHO Medium

QP Audit

Passed audit by the European Union Qualified Person (QP)

Osemitamab (TST001)

- Successfully transitioned from batch to continuous
- Completed osemitamab (TST001) process characterization studies

ADC Service

Started to offer services with new technologies for ADC molecules

Business

Business Development

Multinational Partners to Maximize Asset Value and Accelerate Development

Clinical Trial Collaboration

TRANSCENTA INNOVATE TO EXCEL

Bristol Myers Squibb

In-License

Lilly

Research Collaboration

Dana-Farber Cancer Institute

JOHNS HOPKINS UNIVERSITY

北京大学肿瘤医院 BEIJING CANCER HOSPITAL

上海交通大学 SHANGHAI JIAO TONG UNIVERSITY

上海市肺科医院 SHANGHAI PULMONARY HOSPITAL

Technology-based Partnership

TRANSCENTA INNOVATE TO EXCEL

MERCK

Joint Venture

ALEBUND

03

PART 03

Financial & Outlook

创胜集团
TRANSCENTA

2022 Financial Results

Healthy Financial Profile and Well Capitalized for Growth Initiatives

Key Income Statement Metrics

Revenue

RMB 101.9 million



Other Income

RMB 46.4 million



R&D expenses
(non-IFRS)

RMB 340.5 million



Administrative expenses
(non-IFRS)

RMB 104.9 million



Note:
The difference between IFRS and the non-IFRS is mainly driven by the non-cash share-based compensation expenses booked during the reporting period.

Outlook

Integrated Platform, Cutting-edge Technology, Differentiated and Competitive Biologics

Oncology

Osemitamab (TST001)

- Initiate **a global pivotal trial** for the 1L G/GEJ adenocarcinoma patients
- Multiple data-readouts for chemo combo and nivo combo
- Expand explorations in **other CLDN18.2 expressing solid tumors**

TST003

- Continue phase I study to enable combination trials.
- Announce pre-clinical data at AACR 2023

Novel Agents

- Advance new pipeline molecules into IND-enabling studies
  - ✓ TST010 (Treg depleting mAb)
  - ✓ TST012 (ADCC enhanced mAb)
  - ✓ TST013 (ADC)
- Announce pre-clinical data of TST010 at AACR 2023

Non-oncology

TST002 (Blosozumab)

- Release **interim data in Osemitamab**
- Plan to initiate a Phase II trial study in 2023

TST004

- **File IND** in China for IgA nephropathy

TST008

- Initiate IND-enabling study for SLE

Outlook

Integrated Platform, Cutting-edge Technology, Differentiated and Competitive Biologics

Clinical Development

- **Present** data for TST001 and TST002
- **Accelerate** clinical development
- **Initiate** global Phase III trial for Osemitamab (TST001) in Q3/2023
- **Initiate** Phase II study for TST002
- **Discover** innovative molecules

Research

- **Initiate IND enabling study**
- **Expand** pipeline by designing innovative agents of new modalities (ADC, bispecific etc)
- **Deepen** translation research to enable indication expansion

Business Development

- **Continue discussions** with potential partners
- Continue to **identify, evaluate and build** new technology platforms through collaboration and partnership

CMC & CDMO

- **Develop and grow** CDMO business
- **Expand** service scope including cell culture media development
- To fully **utilize capacities and generate** income

04

PART 04

Q&A

创胜集团
TRANSCENTA

TRANSCENTA

INNOVATE TO EXCEL

THANK YOU!

ir@transcenta.com

05

Appendix

创胜集团
TRANSCENTA

Company Overview

Strong Team

Seasoned Management Team

Xueming Qian, Ph.D.
Co-Founder and CEO
AMGEN

Frank Ye, Ph.D.
EVP, COO
AMGEN gsk

Caroline Germa, M.D.
EVP, CMO
AstraZeneca Bristol Myers Squibb NOVARTIS Pfizer Lilly

Daniel Weng
EVP, CFO
AMGEN GE

Christopher Hwang, Ph.D.
EVP, CTO
SANOFI GENZYME

Xichen Zhang, Ph.D.
SVP, Global Process & Product Development & Manufacturing
AMGEN

Yi Gu, Ph.D.
SVP, Head of Research
Ambrx AstraZeneca

Wen-I Chang, Ph.D.
SVP, Oncology Franchise Strategy
Lilly gsk

Kevin Lin
SD, Corporate Strategy & BD
City of Hope

World-class Renowned SAB

Briggs Morrison, M.D.
Scientific Advisory Board Chairman
Executive Partner | MPM Capital
President | Syndax Pharma
Former CMO | AstraZeneca
Former Head of Clinical Development | Pfizer

Susan Jerian, M.D.
President & CEO | ONCORD INC.
Former Supervisory Medical Officer | CBER, FDA
Former Director Clinical Research | Amgen Inc.

Pasi A. Jänne, M.D., Ph.D.
Director | Lowe Center for Thoracic Oncology
Director | Belfer Center for Applied Cancer Science
Professor | Harvard Medical School

Ling Su, Ph.D.
Professor & Director | Institute of Drug Regulatory Science, Shenyang Pharmaceutical University
Venture Partner | Lilly Asia Ventures

Li Xu, M.D. MBA
Strategic advisor to CEO
Venture Partner, LAV
Former VP, Clinical Development, Pfizer
Former Head of Oncology Development, Hengrui

- Top tier scientists
- Long track record in biopharma / biotech
- Held senior leadership positions at MNCs
- Academic excellence